Elotuzumab in combination with pomalidomide and dexamethasone (EloPd) in relapsed refractory multiple myeloma (RRMM): a network meta-analysis

被引：0
|
作者：
Farrell, James [1 ]
Bertin, Nicolas [2 ]
Fischer, Claire [3 ]
Gauthier, Aline [4 ]
机构：
[1] Bristol Myers Squibb, Dublin, Ireland
[2] Amaris, Hlth Econ & Market Access, Paris, France
[3] Amaris, Hlth Econ & Market Access, Montreal, PQ, Canada
[4] Amaris, Hlth Econ & Market Access, Barcelona, Spain
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-244
引用
下载
收藏
页码：S169 / S170
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)
    Badros, Ashraf Z.
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander M.
    Rapoport, Aaron P.
    Kocoglu, Mehmet H.
    Lederer, Emily
    Philip, Sunita
    Lesho, Patricia
    Johnson, Ashlee
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2016, 128 (22)
  • [2] Elotuzumab in Combination with Pomalidomide and Corticosteroids for Relapsed or Refractory Multiple Myeloma
    Sidiqi, Hasib
    McGregor, Scott
    Baker, Ross
    Carnley, Ben
    Radeski, Dejan
    Barraclough, Allison
    Augustson, Bradley
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E83 - E84
  • [3] A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra A.
    Mann, Mason L.
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD, 2019, 134
  • [4] Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
    Chen, Christine I.
    Bahlis, Nizar J.
    Gasparetto, Cristina
    Tuchman, Sascha A.
    Lipe, Brea
    Baljevic, Muhamed
    Kotb, Rami
    Sutherland, Heather J.
    Bensinger, William I.
    Sebag, Michael
    LeBlanc, Richard
    Venner, Christopher P.
    Schiller, Gary J.
    Lentzsch, Suzanne
    Callander, Natalie S.
    Rossi, Adriana C.
    Sheehan, Heidi
    Van Domelen, Dane
    Kazuharu, Kai
    Wang, Hongwei
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    White, Darrell J.
    BLOOD, 2020, 136
  • [5] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew Jenho
    Laubach, Jacob
    Campagnaro, Erica Leigh
    Lipe, Brea
    Nadeem, Omar
    Cole, Craig
    O'Donnell, Elizabeth
    Schlossman, Robert L.
    Bianchi, Giada
    Branagan, Andrew Robert
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra Ann
    Mann, Mason L.
    Lohr, Jens Guenter
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Laplant, Betsy
    Alegria, Victoria R.
    Elliott, Jamie B.
    Sher, Taimur
    Paulus, Aneel
    Chapin, Dustin
    Heslop, Keisha
    Chanan-Khan, Asher
    Roy, Vivek
    BLOOD, 2022, 140 : 4450 - 4451
  • [7] Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma
    Eleutherakis-Papaiakovou, Evangelos
    Gavriatopoulou, Maria
    Ntanasis-Stathopoulos, Ioannis
    Kastritis, Efstathios
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (11) : 921 - 928
  • [8] AN INDIRECT COMPARISON OF ELOTUZUMAB, CARFILZOMIB, AND DARATUMUMAB WHEN GIVEN IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Potluri, R.
    Chen, C.
    Ranjan, S.
    Kumar, A.
    Bhandari, H.
    Davis, C.
    VALUE IN HEALTH, 2019, 22 : S104 - S104
  • [9] Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma ( RRMM) Patients
    不详
    BLOOD, 2021, 138
  • [10] Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis
    Luo, Ying
    Li, Chen
    Niu, Yuanchen
    Wu, Shuanzhi
    Tian, Jingyuan
    Hu, Zhiqin
    He, Jin
    Zhang, Zhixin
    Liu, Haiyan
    Li, Yongmei
    Wang, Tenghua
    Fang, Yi
    EXPERT REVIEW OF HEMATOLOGY, 2024, 17 (4-5) : 127 - 134
12345